Talphera

TLPH · NASDAQ

$1.07−$0.01 (−0.93%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $1.08

Latest news

Press releaseSep 3, 8:30 AM ETPRNewswire
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Press releaseAug 12, 4:05 PM ETPRNewswire
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseAug 5, 4:05 PM ETPRNewswire
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
NewsMay 13, 5:40 PM ET
Talphera Q1 2026 Earnings Call Transcript
Press releaseMay 13, 4:05 PM ETPRNewswire
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseMay 7, 4:05 PM ETPRNewswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
NewsApr 9, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseMar 25, 8:30 AM ETPRNewswire
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
Press releaseMar 23, 8:30 AM ETPRNewswire
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Press releaseMar 18, 4:05 PM ETPRNewswire
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
Press releaseMar 2, 8:30 AM ETPRNewswire
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
NewsFeb 11, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 12, 4:05 PM ETPRNewswire
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
NewsNov 11, 12:13 PM ET
Earnings Outlook For Talphera
Press releaseNov 5, 4:05 PM ETPRNewswire
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
Press releaseOct 21, 8:30 AM ETPRNewswire
Talphera Announces the Appointment of Joe Todisco to Board of Directors
Press releaseSep 8, 8:30 AM ETPRNewswire
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
Press releaseSep 8, 8:30 AM ETGlobe Newswire
CorMedix Announces Strategic Minority Investment in Talphera
Press releaseAug 25, 8:30 AM ETPRNewswire
Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial
NewsAug 19, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 14, 4:05 PM ETPRNewswire
Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
NewsAug 14, 4:32 AM ET
Earnings Scheduled For August 14, 2025
NewsAug 13, 1:02 PM ET
A Preview Of Talphera's Earnings
Press releaseAug 7, 4:35 PM ETPRNewswire
Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025
Press releaseMay 14, 4:05 PM ETPRNewswire
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
NewsMay 14, 4:32 AM ET
Earnings Scheduled For May 14, 2025
NewsMay 13, 5:03 PM ET
Uncovering Potential: Talphera's Earnings Preview
Press releaseMay 7, 4:05 PM ETPRNewswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
Press releaseMar 31, 4:05 PM ETPRNewswire
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Press releaseMar 31, 8:30 AM ETPRNewswire
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
NewsMar 28, 1:02 PM ET
Earnings Outlook For Talphera
Press releaseMar 26, 4:38 PM ETPRNewswire
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
Press releaseJan 14, 8:30 AM ETPRNewswire
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Press releaseNov 24, 7:27 PM ETPRNewswire
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Press releaseNov 13, 4:05 PM ETPRNewswire
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera Q1 2026 Earnings Call Transcript

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Earnings Scheduled For May 13, 2026

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 12, 2025

Earnings Outlook For Talphera

Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

Talphera Announces the Appointment of Joe Todisco to Board of Directors

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CorMedix Announces Strategic Minority Investment in Talphera

Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

12 Health Care Stocks Moving In Tuesday's After-Market Session

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For August 14, 2025

A Preview Of Talphera's Earnings

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For May 14, 2025

Uncovering Potential: Talphera's Earnings Preview

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Earnings Outlook For Talphera

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update